Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001923-38
    Sponsor's Protocol Code Number:KTE-C19-108
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2018-11-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-001923-38
    A.3Full title of the trial
    Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Estudio multicéntrico de fase 1/2 para evaluar la seguridad y la eficacia de
    KTE-C19 en sujetos adultos con leucemia linfocítica crónica en recaída o refractaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 1/2 Multicenter Study of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Estudio multicéntrico de fase 1/2 de KTE-C19 en sujetos adultos con
    leucemia linfocítica crónica en recaída o refractaria
    A.3.2Name or abbreviated title of the trial where available
    ZUMA-8
    A.4.1Sponsor's protocol code numberKTE-C19-108
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorKite Pharma, Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportKite Pharma, Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationKite Pharma, Inc
    B.5.2Functional name of contact pointRegulatory Affairs
    B.5.3 Address:
    B.5.3.1Street Address2400 Broadway
    B.5.3.2Town/ citySanta Monica
    B.5.3.3Post codeCA 90404
    B.5.3.4CountryUnited States
    B.5.6E-mailregulatory@kitepharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/15/1572
    D.3 Description of the IMP
    D.3.2Product code KTE-X19
    D.3.4Pharmaceutical form Dispersion for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNKTE-X19
    D.3.9.2Current sponsor codeKTE-X19
    D.3.9.4EV Substance CodeSUB193905
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number200000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/15/1572
    D.3 Description of the IMP
    D.3.2Product code KTE-X19
    D.3.4Pharmaceutical form Dispersion for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNKTE-X19
    D.3.9.2Current sponsor codeKTE-X19
    D.3.9.4EV Substance CodeSUB193905
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number100000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/15/1572
    D.3 Description of the IMP
    D.3.2Product code KTE-X19
    D.3.4Pharmaceutical form Dispersion for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNKTE-X19
    D.3.9.2Current sponsor codeKTE-X19
    D.3.9.4EV Substance CodeSUB193905
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number50000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed/Refractory Chronic Lymphocytic Leukemia
    leucemia linfocítica crónica en recaída o refractaria
    E.1.1.1Medical condition in easily understood language
    Cancers of white blood cells
    cancer de celulas blancas
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10008977
    E.1.2Term Chronic lymphocytic leukemia recurrent
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10008978
    E.1.2Term Chronic lymphocytic leukemia refractory
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1: Evaluate the safety of KTE-X19
    Phase 2: Evaluate the efficacy of KTE-X19 as measured by the objective response rate (ORR) per independent review
    Fase 1: evaluar la seguridad de KTE-X19
    fase 2: evaluar la eficacia de KTE-X19 en términos de la tasa de respuesta objetiva (TRO) determinada mediante revisión independiente
    E.2.2Secondary objectives of the trial
    Characterize the safety profile and assess additional efficacy endpoints
    Caracterizar el perfil de seguridad y evaluar criterios de valoración de la eficacia adicionales
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    101. Documentation of relapsed or refractory CLL AND a minimum of two prior treatment regimens with progression on treatment with ibrutinib
    102. An indication for treatment per IWCLL 2018 criteria and radiographically measurable disease (at least 1 lesion > 1.5cm in diameter)
    103. Adequate hematologic function
    104. Adequate renal, hepatic, cardiac and pulmonary function
    105. Age 18 or older
    106. ECOG performance status of 0 or 1
    107. Females of childbearing potential must have a negative serum or urine pregnancy test
    101. LLC en recaída o refractaria documentada y, como mínimo, dos pautas de tratamiento previas con progresión de la enfermedad en el tratamiento con ibrutinib.
    102. Tratamiento indicado de acuerdo con los criterios del IWCLL de 2018 y enfermedad radiológicamente medible (al menos 1 lesión >1,5 cm de diámetro).
    103. Actividad hematológica adecuada.
    104. Actividades renal, hepática, cardiaca y pulmonar adecuadas.
    105. 18 años de edad o más.
    106. Escala de valoración del ECOG de 0 o 1.
    107. Las pacientes mujeres potencialmente fértiles deben obtener un resultado negativo en la prueba de embarazo en suero o orina.
    E.4Principal exclusion criteria
    201. A history of treatment including any of the following:
    a. Prior CD19 directed therapy
    b. Treatment with alemtuzumab within 6 months before enrollment
    c. Prior allogeneic hematopoietic stem cell transplant or donor lymphocyte infusion within 6 months prior to enrollment
    d. Live vaccine administration within 4 weeks before enrollment
    e. Systemic immunosuppression or systemic treatment for any autoimmune disease not related to CLL in the 2 years before enrollment
    202. Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index
    203. History of autoimmune disease resulting in end-organ injury unless attributable to CLL (eg, ITP, AIHA)
    204. Diagnosis of Richter’s transformation or a history of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg, skin, cervix, bladder, breast), superficial bladder cancer, asymptomatic localized low grade prostate cancer for which watch-and-wait approach is standard of care, or any other cancer that has been in remission for > 3 years prior to enrollment
    205. History of severe hypersensitivity reaction attributed to aminoglycosides or any of the agents required for treatment in this study
    206. CNS disease
    207. History of concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome
    208. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months before enrolment
    209. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before enrollment
    210. Primary immunodeficiency
    211. Known infection with HIV; chronic active hepatitis B; active hepatitis C. A history of hepatitis B or C is permitted if the viral load is undetectable by quantitative PCR or a comparable testing method.
    212. Presence of active fungal, bacterial, viral infection or any infection requiring antimicrobial treatment for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite Medical
    Monitor
    213. Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are permitted
    217. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
    201. Antecedentes de tratamiento, incluidos cualesquiera de los siguientes:
    a. Tratamiento dirigido específicamente contra el CD19.
    b. Tratamiento con alemtuzumab en los 6 meses anteriores a la inclusión.
    c. Trasplante alogénico de células madre hematopoyéticas o infusión de linfocitos de donante en los 6 meses anteriores a la inclusión.
    d. Administración de una vacuna atenuada en las 4 semanas anteriores a la inclusión.
    e. Inmunosupresión sistémica o tratamiento sistémico para cualquier enfermedad autoinmunitaria no relacionada con la LLC en los 2 años anteriores a la inclusión.
    202. EICH aguda de grado II-IV según los criterios de Glucksberg o de gravedad B-D según el índice IBMTR.
    203. Antecedentes de enfermedad autoinmunitaria que haya resultado en una lesión orgánica irreversible, a menos que pueda atribuirse a la LLC (p. ej., PIT, AHAI).
    204. Diagnóstico de transformación de Richter o antecedentes de malignidad que no sea cáncer de piel no melanocítico o carcinoma in situ (p. ej., en la piel, cuello del útero, vejiga, mama), cáncer de vejiga superficial, cáncer de próstata de bajo grado localizado asintomático para el que se indica una estrategia de vigilancia y espera como práctica clínica habitual o cualquier otro cáncer en remisión durante >3 años antes de la inclusión.
    205. Antecedentes de reacción de hipersensibilidad grave atribuida a aminoglucósidos o a cualesquiera de los agentes requeridos para el tratamiento en este estudio.
    206. Enfermedad del SNC.
    207. Antecedentes de síndrome genético concomitante asociado con insuficiencia de médula ósea, como anemia de Fanconi, síndrome de Kostmann y síndrome de Shwachman-Diamond.
    208. Antecedentes de infarto de miocardio, angioplastia coronaria o implantación de endoprótesis, angina inestable u otra enfermedad cardiaca clínicamente significativa en los 12 meses anteriores a la inclusión.
    209. Antecedentes de trombosis venosa profunda o embolia pulmonar sintomáticas en los 6 meses anteriores a la inclusión.
    210. Inmunodeficiencia primaria.
    211. Infección por VIH conocida; hepatitis B activa crónica; hepatitis C activa. Se admiten antecedentes de hepatitis B o C si la carga viral es indetectable mediante RPC cuantitativa o un método de prueba similar.
    212. Presencia de infección fúngica, bacteriana o vírica activa, o cualquier infección que requiera tratamiento antimicrobiano. Se admiten ITU simples y faringitis bacteriana sin complicaciones si responden al tratamiento activo y después de consultar con Kite Medical.
    Supervisión
    213. Presencia de tubos o sondas insertados (p. ej., sonda de nefrostomía percutánea, sonda de Foley insertada, sonda de drenaje biliar, sonda pleural/peritoneal/pericárdica). Se admiten reservorios de Ommaya y catéteres de acceso venoso central dedicados, como catéteres Port-a-Cath o Hickman.
    217. Cualquier afección médica que pueda interferir con la evaluación de la seguridad o eficacia del tratamiento del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1: Incidence of DLTs in subjects treated with KTE-X19
    Phase 2: Objective response rate (CR/CRi/PR) per independent review as defined by IWCLL 2018 criteria
    Fase I: Incidencia de TLD en sujetos tratados con KTE-X19
    Fase II: Tasa de respuesta objetiva (RC/RCi/RP) determinada mediante revisión independiente, tal y como se define en los criterios del IWCLL de 2018
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase 1: onset within the first 28 days following KTE-X19 infusion
    Phase 2: Disease assessment at D28, W8, M3
    Fase I: aparición durante los primeros 28 días posteriores a la infusión de KTE-X19
    Fase II: Evaluación de la enfermedad en D28, S8, M3
    E.5.2Secondary end point(s)
    Complete response (CR/CRi) rate,
    ORR per investigator review
    Minimum Residual Disease (MRD) Negative Rate
    CR/CRi with MRD- (CR/MRD-) rate
    Duration of response (DOR),
    Progression-free survival (PFS)
    Overall survival (OS)
    Incidence of AEs and clinically significant changes in laboratory values
    Changes in EQ-5D and FACT-Leu
    Tasa de respuesta completa (RC/RCi), TRO según revisión del investigador
    Tasa de enfermedad residual mínima (ERM) negativa
    RC/RCi con tasa ERM- (RC/ERM-)
    Duración de la respuesta (DDR),
    Supervivencia sin progresión (SSP)
    Supervivencia total (ST)
    Incidencia de AA y cambios clínicamente significativos en los valores de laboratorio
    Cambios en los cuestionarios EQ-5D y FACT-Leu
    E.5.2.1Timepoint(s) of evaluation of this end point
    Disease Assessment at D28, W8, M3, M6, then every 3 months till M24, then every 6 months till M60, them annually through Year 15
    Safety: onset on or after the KTE-X19 infusion, through the study
    Evaluación de la enfermedad en D28, S8, M3, M6; después, cada 3 meses hasta M24; después, cada 6 meses hasta M60, y, por último, cada año hasta el año 15
    Seguridad terapéutica: aparición con la infusión de KTE-X19 o después, durante todo el estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Dose escalation
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Germany
    Italy
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS; All enrolled subjects will be followed in the long-term follow-up period for safety, survival and disease status, if applicable, for up to 15 years after KTE-X19 Infusion.
    Ultima visita del ultimo paciente: se realizara un seguimiento de todos los sujetos incluidos en el periodo de seguimiento a largo plazo por seguridad, supervivencia y estado de la enfermedad, si aplica, hasta 15 años despues de la infusion de KTE-X19
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years17
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years17
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 30
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 78
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 108
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    expected normal treatment of that condition at discretion of the investigator
    tratamiento habitual esperado para dicha condicion a discrecion del Investigador
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-02-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-01-31
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 22:53:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA